STOCK TITAN
  1. Home
  2. News
  3. CSLLY

CSL Ltd. - CSLLY STOCK NEWS

Welcome to our dedicated news page for CSL Ltd. (Ticker: CSLLY), a resource for investors and traders seeking the latest updates and insights on CSL Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CSL Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CSL Ltd.'s position in the market.

News
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Rhea-AI Summary
CSL Vifor and Travere Therapeutics receive conditional marketing authorization from the European Commission for FILSPARI (sparsentan) for the treatment of IgA Nephropathy, marking a significant advancement in non-immunosuppressive therapy for this rare kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
News
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
Rhea-AI Summary
CSL Vifor receives Health Canada authorization for Ferinject to treat iron deficiency anemia and heart failure, expanding treatment options for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
News
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
Rhea-AI Summary
CSL Seqirus is prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season following FDA recommendations. The company will transition to trivalent formulations, excluding the B/Yamagata strain. CSL Seqirus received FDA approval for its trivalent vaccines and aims to improve vaccine confidence and immunization rates globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
News
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Rhea-AI Summary
CSL Limited reports strong financial performance with revenue of $8.05 billion, a 11% increase. Net profit after tax is $1.90 billion, up 20% on a constant currency basis. CSL Behring's portfolio growth, especially in immunoglobulins, drove the positive results. The company reaffirms its guidance for FY24 with anticipated NPATA of $2.9 billion to $3.0 billion at constant currency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
none
-
News
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
Rhea-AI Summary
CSL (ASX:CSL; USOTC:CSLLY) announces Phase 3 AEGIS-II trial results for CSL112, which did not meet primary efficacy endpoint of MACE reduction at 90 days. No immediate regulatory filing planned. Ongoing analysis to be presented at ACC Scientific Sessions in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.72%
Tags
clinical trial
-
News
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Rhea-AI Summary
A study conducted by Meiji Seika Pharma in Japan compared ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, with a conventional mRNA COVID-19 vaccine. The data showed that ARCT-154 induces a longer immune response and has an advantage in antibody persistence compared to the conventional vaccine. The study demonstrated the continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of the duration of the immune response. The sa-mRNA technology has the potential to provide significant advancements over conventional mRNA vaccines including prolonged protection at lower doses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
covid-19
News
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Rhea-AI Summary
CSL and Arcturus Therapeutics announce positive results of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine. The study conducted in Japan demonstrates Immunological Non-Inferiority to Wuhan Strain and Superior Immunogenicity to Omicron BA.4/5 Variant. The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant, and an advantage in antibody persistence. The results follow the approval of the world's first sa-mRNA COVID-19 vaccine for adults by Japan Ministry of Health, Labor and Welfare in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
covid-19
-
News
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
Rhea-AI Summary
CSL Behring's survey results show that patients with CIDP prioritize convenience and flexibility in treatment, with a majority interested in exploring more convenient treatment options and administering treatment at home. However, less than half of the patients discuss potential new treatment options or switching treatments with a physician. The survey also revealed that patients wish their physicians better understood their priorities in CIDP treatment, including efficacy, minimal side effects, condition maintenance, at-home administration, and flexible dosing options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
none
-
News
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
Rhea-AI Summary
CSL Behring (CSL) introduces a 10g prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid), the #1 immune globulin prescribed for Primary Immunodeficiency (PI) and the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
News
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Rhea-AI Summary
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty®. ARCT-154 results were achieved with one sixth the dose of Comirnaty® (5 μg vs 30 μg). The study included healthy adults initially immunized with two doses of an mRNA vaccine (Comirnaty® or Spikevax™) and then a third dose of Comirnaty® at least three months prior to the booster dose of either ARCT-154 or Comirnaty® in the study. Both vaccines were well-tolerated, with no causally associated severe or serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
Stock CSLLY logo
CSL Ltd.

OTC:CSLLY

CSLLY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CSLLY Stock Data

89.03B
482.67M
0.02%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Australia
Melbourne